Please use this identifier to cite or link to this item:
Title: 1464P - KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
Authors: Rodriguez Abreu, D.
Garassino, M.C.
Esteban, E.
Speranza, G.
Felip, E.
Domine, M.
Hochmair, M.J.
Powell, S.F.
Cheng, S.Y.-S.
Bischoff, H.
Peled, N.
Hui, R.
Reck, M.
Garon, E.B.
Boyer, M.
Grossi, F.
Jennens, R.
Yang, J.
Pietanza, M.C.
Gadgeel, S.M.
UNESCO Clasification: 320101 Oncología
Issue Date: 2018
Journal: Annals of Oncology 
Conference: European-Society-for-Medical-Oncology Asia Congress 
Abstract: In KEYNOTE-189 (NCT02578680), pembro plus pem and platinum provided superior OS (HR 0.49, P < .00001) and PFS (HR 0.52, P < .00001) and had manageable safety vs placebo plus pem and platinum as first-line therapy for metastatic nonsquamous NSCLC. In an exploratory analysis, we assessed outcomes by investigator’s choice of carboplatin (carbo) or cisplatin (cis).
ISSN: 0923-7534
DOI: 10.1093/annonc/mdy292.086
Source: Annals of Oncology [0923-7534], n. 29 (supl. 8)
Appears in Collections:Actas de congresos
Show full item record

Page view(s)

checked on Aug 12, 2023

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.